002864 Stock Overview Researches and develops, produces, and sells Chinese patent medicines in China. More details
Rewards Risk Analysis No risks detected for 002864 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Shaanxi Panlong Pharmaceutical Group Limited By Share Historical stock prices Current Share Price CN¥26.27 52 Week High CN¥34.88 52 Week Low CN¥22.00 Beta -0.19 1 Month Change -12.84% 3 Month Change -7.04% 1 Year Change -20.42% 3 Year Change 4.04% 5 Year Change -5.23% Change since IPO 81.93%
Recent News & Updates
Investor sentiment deteriorates as stock falls 17% Jan 10 Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Announces the Profit Distribution Proposal for the Third Quarter of 2024 Jan 04
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Dec 31
Third quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.33 in 3Q 2023) Oct 28
Now 20% overvalued Oct 18
Investor sentiment improves as stock rises 17% Oct 02 See more updates
Investor sentiment deteriorates as stock falls 17% Jan 10 Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Announces the Profit Distribution Proposal for the Third Quarter of 2024 Jan 04
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Dec 31
Third quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.33 in 3Q 2023) Oct 28
Now 20% overvalued Oct 18
Investor sentiment improves as stock rises 17% Oct 02
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2024 Results on Oct 28, 2024 Sep 30
Now 27% overvalued after recent price rise Sep 30
There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding Sep 30
New major risk - Financial data availability Sep 17
Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 2Q 2023) Aug 28
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2024 Results on Aug 28, 2024 Jun 29
Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year May 31
Dividend increased to CN¥0.22 May 30
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 03 June 2024 May 29
We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings May 02
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd, Annual General Meeting, May 21, 2024 Apr 28
Now 21% overvalued Apr 27
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for the Year 2023 Apr 27
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q1, 2024 Results on Apr 26, 2024 Mar 30 Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) announces an Equity Buyback for CNY 20 million worth of its shares. Mar 15
Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32% Mar 06
Investor sentiment deteriorates as stock falls 15% Feb 01
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Dec 30
New minor risk - Share price stability Nov 22
Third quarter 2023 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in 3Q 2022) Nov 03
Investor sentiment improves as stock rises 18% Nov 02
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2023 Results on Oct 30, 2023 Sep 30
Investor sentiment improves as stock rises 16% Sep 28
Second quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 2Q 2022) Aug 24
New minor risk - Dividend sustainability Jul 05
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2023 Results on Aug 24, 2023 Jul 01
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd. Approves Cash Dividend for 2022 May 24
Insufficient new directors May 04
First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.23 in 1Q 2022) Apr 29
Investor sentiment improves as stock rises 21% Apr 27
Investor sentiment improves as stock rises 15% Mar 21
Investor sentiment improved over the past week Dec 13
Investor sentiment improved over the past week Nov 10 Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it expects to receive CNY 302 million in funding Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 3Q 2021) Oct 29
Now 20% undervalued after recent price drop Oct 21
Investor sentiment improved over the past week Oct 18
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Management Appointments Sep 14
Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.29 in 2Q 2021) Aug 26
Investor sentiment improved over the past week Jun 09
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Approves 2021 Profit Distribution Plan May 19
Investor sentiment improved over the past week May 09
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for 2021 Apr 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations Apr 27
Investor sentiment deteriorated over the past week Apr 11
Investor sentiment improved over the past week Mar 16
Investor sentiment improved over the past week Dec 13
Third quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.39 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.27 in 2Q 2020) Aug 24
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd. Announces Cash Dividend for the Year 2020, Payable on May 31, 2021 May 26
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Cash Dividend for the Year 2020 May 08
Full year 2020 earnings released: EPS CN¥0.92 (vs CN¥0.83 in FY 2019) Apr 14
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2020 Results on Apr 13, 2021 Feb 24
New 90-day low: CN¥22.24 Jan 29
New 90-day low: CN¥23.85 Jan 11
New 90-day low: CN¥25.17 Dec 24
Third quarter earnings released Oct 28
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2020 Results on Oct 27, 2020 Oct 20
New 90-day low: CN¥25.52 Sep 28
New 90-day low - CN¥27.25 Sep 09
Earnings released Aug 25
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2020 Results on Aug 25, 2020 Aug 04 Shareholder Returns 002864 CN Pharmaceuticals CN Market 7D 0% -0.05% 0.9% 1Y -20.4% -1.2% 11.5%
See full shareholder returns
Return vs Market: 002864 underperformed the CN Market which returned 11.5% over the past year.
Price Volatility Is 002864's price volatile compared to industry and market? 002864 volatility 002864 Average Weekly Movement 6.1% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 6.9% 10% most volatile stocks in CN Market 10.9% 10% least volatile stocks in CN Market 4.1%
Stable Share Price: 002864 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002864's weekly volatility (6%) has been stable over the past year.
About the Company Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chinese medicine anti-inflammatory products. The company was founded in 1997 and is based in Xi'an, China.
Show more Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Fundamentals Summary How do Shaanxi Panlong Pharmaceutical Group Limited By Share's earnings and revenue compare to its market cap? 002864 fundamental statistics Market cap CN¥2.76b Earnings (TTM ) CN¥115.90m Revenue (TTM ) CN¥981.52m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 002864 income statement (TTM ) Revenue CN¥981.52m Cost of Revenue CN¥388.49m Gross Profit CN¥593.03m Other Expenses CN¥477.13m Earnings CN¥115.90m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 25, 2025
Earnings per share (EPS) 1.10 Gross Margin 60.42% Net Profit Margin 11.81% Debt/Equity Ratio 9.3%
How did 002864 perform over the long term?
See historical performance and comparison Dividends
0.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/25 23:49 End of Day Share Price 2025/01/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Song Yang Tianfeng Securities Brokerage Co., Ltd Tielin Chen Topsperity Securities
Show 0 more analysts 
